These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 26830084

  • 1. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.
    Ruhlmann M, Binse I, Bockisch A, Rosenbaum-Krumme SJ.
    Nuklearmedizin; 2016 Jun 28; 55(3):99-103. PubMed ID: 26830084
    [Abstract] [Full Text] [Related]

  • 2. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Jun 28; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

  • 3. Role of 18F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients.
    Piccardo A, Trimboli P, Puntoni M, Foppiani L, Treglia G, Naseri M, Bottoni GL, Massollo M, Sola S, Ferrarazzo G, Bruzzone M, Catrambone U, Arlandini A, Paone G, Ceriani L, Cabria M, Giovanella L.
    Thyroid; 2019 Apr 28; 29(4):549-556. PubMed ID: 30864903
    [Abstract] [Full Text] [Related]

  • 4. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S, Aksoy SY, Vatankulu B, Aliyev A, Uslu L, Ozhan M, Sager S, Halac M, Sonmezoglu K.
    Ann Nucl Med; 2014 Dec 28; 28(10):970-9. PubMed ID: 25120245
    [Abstract] [Full Text] [Related]

  • 5. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice.
    Kukulska A, Krajewska J, Kołosza Z, Paliczka-Cies Lik E, Puch Z, Gubała E, Król A, Kalemba M, Kropin Ska A, Jarząb B.
    Eur J Endocrinol; 2016 Nov 28; 175(5):379-85. PubMed ID: 27511823
    [Abstract] [Full Text] [Related]

  • 6. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
    Triviño Ibáñez EM, Muros MA, Torres Vela E, Llamas Elvira JM.
    Endocrine; 2016 Mar 28; 51(3):490-8. PubMed ID: 26224589
    [Abstract] [Full Text] [Related]

  • 7. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, Nakamoto Y, Higashi T, Saga T, Konishi J.
    Eur J Nucl Med Mol Imaging; 2004 Apr 28; 31(4):491-8. PubMed ID: 14666387
    [Abstract] [Full Text] [Related]

  • 8. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E, Aras G, Kucuk NO.
    Clin Nucl Med; 2013 May 28; 38(5):326-31. PubMed ID: 23486319
    [Abstract] [Full Text] [Related]

  • 9. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.
    Head Neck; 2018 Jan 28; 40(1):94-102. PubMed ID: 29130586
    [Abstract] [Full Text] [Related]

  • 10. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M, Ung YC, Ehrlich L, Silverberg J, Balogh J, Wong CS.
    J Otolaryngol Head Neck Surg; 2008 Oct 28; 37(5):712-7. PubMed ID: 19128681
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A.
    Clin Nucl Med; 2012 Oct 28; 37(10):953-9. PubMed ID: 22899202
    [Abstract] [Full Text] [Related]

  • 12. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan 28; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A, Kaznowski J, Wolinski K, Jodlowska E, Michaliszyn P, Kubiak K, Czepczynski R, Ruchala M.
    Nucl Med Commun; 2016 Sep 28; 37(9):935-8. PubMed ID: 27383190
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
    Ma C, Wang X, Shao M, Zhao L, Jiawei X, Wu Z, Wang H.
    Q J Nucl Med Mol Imaging; 2015 Jun 28; 59(2):220-7. PubMed ID: 24844253
    [Abstract] [Full Text] [Related]

  • 18. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
    Sabet A, Binse I, Grafe H, Ezziddin S, Görges R, Poeppel TD, Bockisch A, Rosenbaum-Krumme SJ.
    Eur J Nucl Med Mol Imaging; 2016 Oct 28; 43(11):1988-94. PubMed ID: 27118127
    [Abstract] [Full Text] [Related]

  • 19. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
    Esteva D, Muros MA, Llamas-Elvira JM, Jiménez Alonso J, Villar JM, López de la Torre M, Muros T.
    Ann Surg Oncol; 2009 Jul 28; 16(7):2006-13. PubMed ID: 19415387
    [Abstract] [Full Text] [Related]

  • 20. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
    Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA.
    Head Neck; 2012 May 28; 34(5):626-31. PubMed ID: 21850699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.